ArticlePLOS global public health2025
Use of machine learning in predicting continuity of HIV treatment in selected Nigerian States.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mortality Prediction Among People Living With HIV on Antiretroviral Therapy in Public Health Facilities in Gondar City Administration, Northwest Ethiopia: Machine Learning-Based Study.JMIR medical informatics · 2026Article
- Applying Machine Learning to Predict Loss to Follow-Up Among People Living With HIV in Haiti Using a National Electronic Medical Record Cohort.International journal of public health · 2026Article
- Predicting and identifying correlates of inequalities in breast cancer screening uptake using national level data from India.Frontiers in artificial intelligence · 2025Article
- Exploring the role of artificial intelligence toward management of HIV and TB co-infection in Nigeria: a comprehensive narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nigeria, with the second-largest HIV epidemic globally, faces challenges in achieving its HIV epidemic control goals by 2030, with interruptions in treatment (IIT) a significant challenge. Machine learning (ML) models can help HIV programs implement targeted interventions to improve the quality of care, develop effective early interventions, and provide insights into optimal resource allocation and program sustainability. This paper aims to identify predictors and measure the performance of models used to predict the risk of IIT among People Living with HIV (PLHIV) on antiretroviral therapy (ART). We trained multiple supervised ML algorithms on de-identified client-level electronic medical records data from a cohort of PLHIV across four Nigerian states. Merged demographic, clinic, pharmacy, and laboratory data were included as potential predictor variables in multiple models. The study analyzed data from 41,394 PLHIV, with 266,520 observations receiving treatment across four Nigerian states. The overall IIT rate was 33.7%, ranging from 17.7% in Cross River State to 42.4% in Niger State. The AdaBoost model demonstrated the best performance, with a sensitivity of 69.2%, specificity of 82.3%, F1 score of 0.678, and PR-AUC and ROC-AUC values of 0.563 and 0.843, respectively. Key predictors included PLHIV prior behavior, visit history, and geographic factors, while demographic features played a lesser role. This study highlights the utility of ML, particularly the AdaBoost model, in stratifying PLHIV by the risk of IIT. By leveraging ML, HIV programs can implement data-driven, targeted interventions to improve care continuity. However, further research is needed to address data biases and contextual challenges in resource-constrained settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.